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RESUMO 
As vacinas baseadas em DNA plasmídico são uma alternativa mais segura 
relativamente às tradicionais, podendo ser estes vetores produzidos mais rapidamente e 
com maior facilidade no geral. Escherichia coli é o hospedeiro mais comum para a produção 
de vacinas de DNA. Contudo estas bactérias gram negativas possuem na sua membrana 
externa lipopolissacarídeos, uma endotoxina que se liga a um complexo de recetores 
CD14/TLR4/MD2, ativando a cascata do complemento e que resulta numa reação 
inflamatória grave. Assim, este trabalho pretende desenvolver uma alternativa mais segura 
para as vacinas de DNA em bactérias ácido lácticas uma vez que são comumente utilizadas 
na indústria alimentar, são consideradas como probióticos e usadas para a expressão de 
proteínas heterólogas.  
 O crescimento para duas estirpes (Lactococcus lactis LMG 19460 e Lactobacillus 
plantarum CCUG 61730) foi optimizado em pequena escala (crescimento em falcon), 
chegando-se à escala de 1 litro de cultura celular em condições anaeróbias. Para o 
processo de eletrotransformação só o baseado em NaCl foi eficiente para a transformação 
de L. lactis LMG 19460, não se tendo obtido transformantes para L. plantarum CCUG 
61730. Neste trabalho construiu-se um plasmídeo modificado por alteração do Ribosome 
binding site (RBS) de forma a aumentar o número de cópias de plasmídeo em bactérias 
lácticas. A quantificação relativa do número de cópias do plasmídeo foi realizada por PCR 
em tempo real e como análise complementar utilizou-se a quantificação por absorvância a 
260nm após purificação do plasmídeo. Embora haja alguma variação, parece existir um 
aumento do número de cópias do pTRKH3 em L. lactis LMG 19460 em 4 colónias. No 
entanto para outras colónias este aumento não foi tão evidente. A sequência modificada do 
RBS foi confirmada por sequenciação para os clones mais produtores e para os restantes. 
Finalmente, melhorou-se o rendimento de purificação (cerca de 3000%) dos plasmídeos 
adicionando 10mg/ml de lisozima durante o passo de lise celular.  
 
 
 
Palavras chave: Bactérias ácido lácticas, vacinas de DNA, número de cópias de plasmídeo, 
Origens de Replicação, plasmídeo pTRKH3. 
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ABSTRACT 
The vaccines based on plasmid DNA are a safer alternative to the traditional. In general 
plasmid vectors are produced more quickly and easier. Escherichia coli is the most common 
host strain for production of DNA vaccines. However, these gram-negative bacteria have 
lipopolysaccharides in the outer cell membrane, which acts as an endotoxin that binds to a 
complex of CD14/TLR4/MD2 receptors, activating the complement cascade resulting in a 
severe inflammatory reaction. This work aims to develop a safer alternative to DNA vaccines 
in Lactic Acid Bacteria since they are commonly used in the food industry, used as a 
probiotic and also for delivery of therapeutic proteins.  
The process of growth at small scale has been optimized for strains Lactococcus lactis 
LMG 19460 and Lactobacillus plantarum CCUG 61730. It was also produced 1 liter in 
anaerobic conditions. Electrotransformation was achieved with NaCl method only for strain L. 
lactis LMG 19460.  A modified plasmid DNA (pTRKH3) for vaccine with a change in 
Ribosome binding site (RBS) was produced, in order to increase the copy number of plasmid 
in Lactic Acid Bacteria. The relative quantification of plasmid copy number was performed by 
RT-PCR and by absorbance at 260nm after purification by miniprep as a complementary 
analysis. It was found in four clones of L. lactis LMG 19460 harbouring pTRKH3 an 
increased plasmid copy number. However, for other colonies this increase was not so 
evident. Cell disruption and purification process of plasmid DNA was obtained by alkaline 
lysis. It was achieved much higher amounts (3000%) of purified pDNA after addition of 
Lysozyme 10 mg / l to cell lysis. 
 
 
 
 
 
 
Keywords: Lactic acid bacteria, DNA vaccines, plasmid copy number, origins of replication. 
Plasmid pTRKH3.  
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1. BACKGROUND AND GOAL 
The goal of this work is to produce plasmid DNA (pDNA) by Lactic acid bacteria (LAB), to 
use as DNA vaccines.  
Vaccines based on plasmid DNA are very promising tools both for the prevention of 
infectious diseases and for the treatment of acquired diseases. These vaccines have several 
advantages over traditional vaccines, namely the flexible genetic design, lack of infection risk 
and low cost of production in a microbial host [1]. These DNA vaccines are currently 
produced as plasmids in Escherichia coli. In this work, we propose an alternative GRAS 
(generally recognized as safe) host cell system for pDNA production: lactic acid bacteria. The 
established procedures for plasmid production and downstream processing were based in 
Escherichia coli  [2] with some point modifications for LAB. 
E. coli contains highly immunogenic lipopolysaccharides (LPS) that may be co-purified 
with pDNA [1]. In alternative, species of Lactococcus and Lactobacillus genera for pDNA 
production will be used [3] [4]. Lactic acid bacteria are widely used for the manufacturing of 
dairy products, being considered GRAS due to its non-invasive and non-pathogenic nature 
[5]. A major problem while using LAB for pDNA production is the low plasmid copy number 
which leads to low plasmid yields. In order to overcome this problem an increase in the 
number of copies of plasmid per cell will be developed in this work.  
 
1.1 SPECIFIC PURPOSES: 
 
 Production of a higher copy number of an engineered plasmid DNA, thus increasing 
the yield in the production of therapeutic molecules. 
 Optimization of the cell growth of LAB. 
 Optimization of electrocompetent LAB cells. 
 Adaptation of plasmid extraction, separation and purification, considering that LAB 
are quite different from E. coli. 
 
2. STATE OF THE ART  
 
2.1 DNA VACCINES 
Vaccines based on plasmid DNA are an alternative for the prevention of infectious 
diseases (e.g. malaria, tuberculosis, HIV, and others) and the treatment of some 
autoimmune and cancer diseases [2]. This is only possible due to the ability to induce both 
humoral and cellular immune responses against antigens encoded by recombinant DNA. The 
administration of plasmid DNA provides an immune response, including the activation of 
Production of therapeutic plasmid DNA by Lactic Acid Bacteria 
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CD8+ and CD4+ T lymphocytes, which secrete cytokines and have a regulatory role in 
antibody production [6].  
Bacterial plasmid vectors used as DNA vaccines are developed for expression of 
proteins in mammals cells. If compared to virus vector, plasmids vectors have higher safety, 
lower cost and are easy to produce [7]. There are some essential elements in the plasmids 
used as DNA vaccines, as a promoter and a polyadenylation signal (polyA) for expression in 
mammalian cells, a selection marker, a prokaryotic replication origin for plasmid amplification 
in bacteria [7]. The ColE1 bacterial origin of replication found in numerous plasmids pUC 
series derives from Escherichia coli. This origin of replication provides a high plasmid copy 
number, which allows getting larger amounts of purified plasmids. 
The DNA vaccine is taken by Antigen-presenting cell (APC) or others tissue resident 
cells such as muscle cells or stromal cells. The DNA endocytosed by cells remains in the cell 
nucleus without being inserted into the host cell genome [6]. Several encoded antigens may 
be secreted into the extracellular space, and can stimulate B lymphocytes to produce specific 
antibodies as being endocytosed by other APCs. They produced cytokines such as IL-12 and 
as IFN-γ which may act on the target cell which carries the transgene expression. The IFN- γ 
is an important cytokine in modulating of B cells to secrete IgG2a (a specific antigen, present 
in many infections by microorganisms) [6] [8] . 
E. coli is commonly used for the production of DNA vaccines, since it is an organism that 
it’s  easy to grow at high densities [2], has a variety of cloning vectors and it’s physiology and 
genetic is well known. On the other hand, it has a high content of endotoxins like a LPS. 
Thus arises, the need for safer host producers, such as LAB. Currently some studies 
have been made using these organisms for heterologous expression of proteins and as 
vehicles for delivery of DNA [5] [9] [10]. 
 
2.2 LIPOPOLYSACCHARIDES 
The bacterial LPS are a component of outer membrane of the gram-negative bacteria, 
have a molecular mass of 10-20 kDa, and protect the bacterium against the action of bile 
salts and lipophilic antibiotics [11].  
LPS are located in the exoplasmic leaflet of the outer membrane, acts as an endotoxin 
and are strong stimulators of the innate immunity response of a mammalian host, by acting 
as a potent activator of macrophages which induce them to release inflammatory cytokines 
such as, tumor necrosis factor (TNF) and interleukin (IL-1, IL-6 and IL-8). Excessive 
production of cytokines in response to LPS is regarded as the cause of septic shock in 
humans and also the failure of many organs until the patient's death [12] [13]. 
In general, the LPS is a large molecule constituent of an amphipathic lipid (lipid A) 
covalently linked to a hydrophilic polysaccharide [14].  
Production of therapeutic plasmid DNA by Lactic Acid Bacteria 
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The LPS structure (as shown in figure 1) represents the main surface antigen, is 
composed of an outer or distal segment, an O-chain or O-antigen, an outer core segment, an 
inner core segment, and finally, 
the medial lipid A portion [13] 
[15]. It has been proven, in 
previous studies, that the lipid A 
is the endotoxic centre of the 
molecule [12] [14]. 
The O-antigen is composed 
by a sequence of repeating units 
of oligosaccharide, specific to 
each bacterial species and 
strains. The core region is an 
oligosaccharide containing 
characteristic sugar residues, 
Kdo and heptose. However, chemical variation is more limited than that of O-antigen [16]. 
The E. coli type lipid A consists of one glucosamine disaccharide, two phosphates and six 
acyl groups [14] and shows a strong immuno-stimulating response [16].  
What happens is Toll-like receptor 4 (TLR) in association with MD-2 is responsible for 
the recognition of LPS. The TLR is a type I transmembrane protein expressed on immune 
cells. This is a major signaling receptor of the innate immune system and recognizes a wide 
variety of microbial products. The LPS is transferred to TLR4-MD-2 by two accessory 
proteins, LPS-binding protein and CD14 [11] [14]. Thus, it activates the signaling cascade 
leading to the synthesis of inflammatory mediators, like cytokines. Thus, it can be 
differentially stimulated two pathways inflammatory responses. The myeloid differentiation 
primary response protein 88 (MYD88), leads to the production of pro-inflammatory cytokines. 
Whereas the less inflammatory TRIF pathway which stimulates the expression of interferon β 
(IFN β) and inducible genes that are important for adjuvanticity [11]. 
 
2.3 LACTIC ACID BACTERIA (LAB) 
Lactic acid bacteria (LAB) are a group of non-pathogenic and non-invasive gram-positive 
bacteria, which occupy different ecological niches such as digestive tract of human and 
animals [5] [17]. There are several genera of LAB, classified by their morphological and 
physiological characteristics, include species of Lactobacillus, Leuconostoc, Pediococcus 
and Streptococcus [18]. Species of lactobacilli and streptococci are highly represented in 
different mucosal compartments of the human body [18]. These bacteria, which produce 
Figure 1 - General chemical structure of bacterial 
lipopolysaccharides: The portion Rough type LPS (R) do not contain 
specific O-chain, semi-rough type (SR) just contain a repetitive unit of 
specific O-chain, and smooth type (S) contain two or more repetitive 
units of specific O-chain [15]. 
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lactic acid as major product, are used in numerous fermentations processes of animal origin, 
and can be used either alone or together with other organisms [17].  
In the last decades, LAB have demonstrated high interest as mucosal delivery vehicles. 
This follows from to achieve efficient strategies to deliver vaccine antigens, microbicides and 
therapeutics to the mucosal tissues [18]. It is considered as probiotics once “Live 
microorganisms which, when administered in adequate amounts, confer a health benefit on 
the host” [18]. Furthermore, provides some benefits as probiotics in human health, such as 
detoxifying carcinogens, enhancing immune response, metabolizing cholesterol, and others 
[19]. LAB are good candidates for the development of oral vectors, because some strains 
play an important role in maintaining intestinal 
homeostasis and exert beneficial effects. They 
have the capacity to survive the passage 
through the gastrointestinal tract (GIT) and do it 
so makes these bacteria excellent candidates 
for mucosal targeting of therapeutic molecules 
[10]. In figure 2 summarizes the current 
applications of LAB, and the molecules which 
have been produced.  
Lactobacillus genus can remain viable for a 
while in GIT. For example some strains of 
Lactobacillus plantarum, have probiotic effects 
with anti-inflammatory properties [20].  
Also they can grow in the presence and 
absence of oxygen. Lactobacillus plantarum 
secretes antimicrobial compounds that inhibit 
pathogenic gram-positive and gram-negative 
colonies from forming [21]. Lactobacillus strains have a general beneficial effect and thus can 
be used for therapeutic purposes [22].  
 
2.3.1 APPLICATIONS IN HUMAN HEALTH: 
The capability to be administered by the mucosal way represents a significant advantage 
of the use of L. lactis based vectors. Mucosal surfaces (oral, intranasal, vaginal, or rectal) 
represent an important gateway for many pathogens [23]. In the table 1 shows some 
application by LAB and their benefits in human health.  
 
 
 
Figure 2 - Recent applications of LAB delivery 
systems: The single-chain variable fragments 
(scFvs) molecule, could be used for different 
applications (therapy, anti-infectives or passive 
immunization). Not all of these potential applications 
have been published in the literature. [18] 
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Table 1 - Examples of therapeutic molecules produced by recombinant LAB 
Applicability 
in Disease 
Beneficial effects 
Inflammatory 
Bowel 
Disease 
Includes Crohn’s disease and ulcerative colitis. Recombinants LAB produce anti-
inflammatory molecules, such as IL-10. Thus, their direct delivery to the intestinal 
mucosal and preventing their degradation by the high level proteolytic environment 
encountered in the GIT [22] [23]. 
Anti-Tumoral 
 
For example, in a colon rectal cancer, the LAB may reduce the risk by competitive 
exclusion of pathogenic bacteria involved in carcinogenesis. It also reduces the 
activity of procarcinogenic enzymes, such as β-glucuronidase [24]. 
Allergy 
L. lactis vectors showed anti-allergic properties for food allergens in mouse as an 
animal model [23].  
Anti-Viral 
The Interferon-omega (IFN-ω) produced by L. lactis is effective on enteric viral 
infections [23]. 
Body Weight 
and Obesity 
The engineered L. lactis expressing epidermal growth factor (EGF) was proposed to 
have applications in dietary supplements for children during weaning when intestinal 
development is most required [23]. 
 
2.3.2 PLASMIDS IN LAB: 
Several lactic acid bacteria harbor cryptic plasmids (1.5 to >30 kb in size), which 
potentially can serve as vectors [25] [26]. Although most lactobacilli plasmids are smaller 
than 10kb, is known that some plasmids can be larger until 150kb [19]. 
A few known plasmids may encode important traits such as resistance to phages or 
antibiotics, lactose catabolism, production of proteolytic enzymes and encoding different 
bacteriocins [25] [27]. Many of these plasmids are not yet characterized and future may bring 
new information to other molecules which may also be engineered for the development of 
cloning and expression vectors.   
Several Lactobacillus species often harbor a number of these plasmids and DNA 
sequence analysis has revealed that they replicate a rolling circle replication (RCR) 
mechanism, and also theta mechanism [25] [26].  
 
2.4 ORIGINS OF REPLICATION: 
2.4.1 COPY NUMBER CONTROL 
Bacterial plasmids replicate autonomously and may bring benefits to the host, such as 
drug resistance or metabolic pathways. Several resistant natural plasmids have been report 
to carry virulence factors, such as bacteriocins, siderophores, cytotoxins, or adhesion factors 
and virulence plasmids have been described to carry resistance genes [28]. 
The origin of replication determines the plasmid copy number, and their stability is 
affected by copy number. A positive effect of a high copy number is the greater stability of 
the plasmid. On the other hand, a high number of plasmid copies generally decrease the 
growth rate, thus possibly allowing for cells with few plasmids to dominate the culture, once 
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they grow faster. Plasmids that utilize the same replication system cannot co-exist in the 
same bacterial cell, may exist incompatibility [29]. 
Thus, there are two basic systems which control the copy number of the plasmid, 
depending on the type of negative control component used:  
 directly repeated sequences (iterons) that complex with cognate replication (Rep) 
initiator proteins;  
 antisense RNAs that hybridize to a complementary region of an essential RNA, therefore 
termed countertranscribed (ct) RNAs [29] [30]. 
In this last case the ctRNA binds to its 
complimentary RNA (necessary for plasmid 
replication), inhibiting (directly or indirectly) replication 
of the plasmid, (as shown in figure 3). This inhibitory 
ctRNA is synthesized at a higher rate than that of the 
essential RNA, although having a short half-life. This 
happens because the ctRNA is transcribed by a 
constitutive promoter, and its intracellular 
concentration is proportional to plasmid copy number 
[28] [29]. The ctRNAs can regulate plasmid copy 
number (either alone or with the help of proteins).  
Thus, it may be involved in a variety of 
mechanisms including inhibition of primer maturation, 
inhibition of translation of the essential Rep protein, transcriptional attenuation, or inhibition of 
pseudo knot formation [29].The interaction in ctRNA and mRNA promotes formation of the 
terminator and thus can lead to premature termination of Rep mRNA synthesis [31]. 
 
2.4.2 TYPES OF ORIGIN REPLICATION   
Plasmids DNA replicate using two modes, as RCR and theta mechanism. In most RCR 
plasmids, transcription of the initiator gene and leadingstrand replication proceed in the same 
direction. The RCR derived plasmids may not be suitable for the cloning of some genes, 
such as large genes or genes with high GC content, but they are generally high-copy-number 
plasmids (50 copies/cell) and usually contain a pSH71-based replicon (with repC and repA 
genes, from Lactococcus lactis) [3] [4], which encodes a replication initiation protein [19]. To 
overcome this problem it can be used theta replicating plasmids, which are structurally and 
segregationally more stable than RCR plasmids, and can hold larger DNA inserts [5] [32]. 
For example, pAMβ1 replicon based plasmids that contain regulated rep genes [33]. In a 
study,  the spac-I promoter upstream of ORF E was inserted and this plasmid pAMβ1spac 
replicated efficiently resulting in about 100 plasmids copies/cell in Bacillus subtilis [34].  
Figure 3 -  ct-RNA based replication 
control [29] 
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Three classes of theta replicating plasmids are known and designated A, B, and C. 
Class A includes plasmids which encode a replication protein (Rep) and have a characteristic 
replication origin, designated ori A [34].  The figure 4 represents the theta mechanism of 
replication. The origin of replication has a unique 
nucleotide sequence necessary for replication of 
the DNA molecule. DNA replication is initiated at 
the origin (ORI) and continues in both directions 
around the circular molecule, as the growth forks 
move merge and two daughter molecules are 
produced [35]. For cloning in Lactococcus lactis, 
several studies have shown that the theta type 
plasmid  have more stable segregation then the 
RCR type plasmid [36].  
 
2.4.3 REPLICON pAMβ1 
The pAMβ1 plasmid was initially isolated from Enterococus faecalis, is a low copy 
number and the replication is of unidirectional theta [37]. A lot of plasmids that were isolated 
from streptococci and enterococci have much similarity with pAMβ1 replicon. This initial 
mechanism involved Rep protein, the origin and the host encoded DNA polymerase I [31]. 
The initiation of leading strand synthesis occurs within a -44 bp origin located immediately 
downstream of the Rep gene [31]. 
A few elements are involved in this control, and are located within a -1 kb segment 
mapping upstream of the RepE open reading frame (ORF). The repE gene coding for a 
replication protein of 57-kDa [34]. This region is responsible for the copy-control, as shown in 
Figure 5. The synthesis of RepE is strongly controlled, because it is rate limiting for 
replication. It contains two ORFs, D and F, located on the same strand as RepE, and an 
intergenic region of -350 bp carrying two major promoters (PDE and PCT) and two rho-
independent transcription terminators (TDE and TCT) [31] [37]. 
  
Figure 4 - Theta type replication [35] 
Figure 5 - Replicon pAMβ1 [37] 
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It was shown on earlier studies that the PDE promoter is required for transcription of 
the ORF D and REP E gene. However, RepD is not necessary for replication and its function 
remains unknow [38]. Nevertheless, the PCT directs  synthesis of a small countertranscript 
RNA (CT-RNA), complementary to the non-coding region of the ORF D repE mRNA [31] 
[37]. The terminator (TDE) inhibits transcription initiated in the PDE, so, like the other 
terminator (TCT) inhibits transcription of the PCT [37]. 
Based on previous experiments, one can confirm that, TDE is active and is a key element 
in the negative regulation of PDE directed transcription [37] [31]. 
In previous studies it was verified that CopF negatively regulates pAMβ1 replication by 
binding to an operator which is located immediately downstream of the copF gene [37]. 
Thus, the CopF acts as a repressor of the RepE promoter. To test that CopF negatively 
regulates pAMβ1 copy number, by repressing RepE transcription,a few experiments were 
done and was carried out a deletion a upstream KpnI restriction site. So, as consequence 
enabled a slight increase of copies of plasmid [37]. It was also observed which mutations in 
the PCT promoter or in the transcription terminator (TCT), had no effect on CopF mediated 
regulation and did not affect the activity of the promoter and terminator of the 
countertranscript (PCT and TCT) [31]. These experiments showed that CopF acts 
independently of the attenuation system and they also observed that, CopF mediated 
regulation, does not require ORF D. Thus, the countertranscript-driven attenuation 
mechanism in conjuction with CopF regulatory system repress 100-fold the transcription of 
the repE gene [31].  
 
2.5 RIBOSOME BINDING SITE  
Every bacterial mRNA has a ribosome binding site (RBS), for producing polypeptide 
product. The RBS is a sequence upstream of the start codon  where the ribosome binds to 
the mRNA to begin its the translation of the mRNA into a protein [39]. In prokaryotic cells the 
ribosome binding site is denominated Shine Dalgarno sequence (SD) [40]. 
Although transcript properties such as mRNA stability and codon usage are known to 
influence microbial translation, initiation is often the rate-limiting step in translation [41]. It has 
been verified the distance between the SD sequence and the initiation codon affects the 
translation [40]. It have been identified a number of sequence specific with characteristics 
that can decrease translation initiation rates, and therefore result in low expression levels 
[42]. The presence of secondary structure in the 5’ region of the mRNA can limit translation 
due to sequestration of the 16S hybridization region (SD) sequence or the start codon [43]. 
Secondary structures that limit translation efficiency may be present in the 5’ untranslated 
region of the transcript as well as in the coding region downstream of the initiation codon 
[43]. However, it is known that, gram positive bacteria differ in some characteristics of their 
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translational machinery in comparison to gram negative. Thus, a predicted strong RBS can 
have different effects depending on the organism.  
The change of the original RBS in pAMβ1 origin replication, might lead to a higher 
production of RepE protein and therefore more copies of pDNA.  
3. MATERIALS AND METHODS 
The strains Lactococcus lactis (LMG 19460) and Lactobacillus plantarum (CCUG 
61730), which were chosen for this study are both 
natural inhabitants of the gastrointestinal tract [17] 
[44] and also good candidates as delivery vehicles. 
Although these advantages, gene manipulation 
and vector amplification are difficult in LAB. 
Therefore Escherichia coli (strain DH5α) was 
selected to perform these techniques, using a 
shuttle vector for LAB and E.coli. The shuttle vector 
contains the replicons and the genetic markers 
functional in LAB and E.coli. 
The following diagram (figure 6) illustrates all 
phases of the work. The techniques used have 
been optimized taking in account the characteristics 
of the LAB. 
All materials and solutions used were 
previously sterilized by autoclave at 121ºC for 20 
min, and bacterial cells always manipulated in 
sterile conditions in a laminar flow chamber. 
 
 
 
 
 
 
 
 
  
Figure 6 - Process overview - tasks and respective 
units operations 
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3.1 BACTERIAL STRAINS AND PLASMIDS: 
The bacterial strains and plasmids used in this work are show in Table 2.  
Table 2 - Bacterial strains and plasmids 
Strain or plasmid Replicon Characteristics Source 
E. coli DH5α  
F- endA1 glnV44 thi-1 recA1 relA1 
gyrA96 deoR nupG lacZΔM15 hsdR17 
Invitrogen 
Lactococcus lactis 
(LMG 19460) 
 Wild type, plasmid free BCCM Collection 
Lactobacillus 
plantarum (CCUG 
61730 ) 
 Wild type, plasmid free 
Collection of Culture 
University of 
Göteborg 
pTRKH3 
p15A ori, 
pAMβ1 ori 
Tet 
R
, Ery 
R
 
BCCM/LMBP 
collection, University 
of Ghent, Belgium 
 
3.1.1 E. COLI DH5α: 
E. coli DH5α cells were grown in a pre-inoculum overnight at 37°C in 15ml falcon tubes 
containing 5ml of Luria Bertani (LB) medium (20g/L) from Sigma Aldrich supplemented with 
10μg/ml of tetracycline stock solution (10mg/mL) when containing pTRKH3 vector or its 
derivatives, at 37ºC with 250 rpm in an ARALAB orbital shaker model AGITORB 200. When 
cells reached the exponential growth phase they were transferred to 100ml Erlenmeyer flask 
containing 20ml of LB medium and incubated at 37°C and 250 rpm with 20μl of the same 
tetracycline stock solution, for 4-5 hours or until they reach the O.D.600nm of 1-1.5 measured 
in U-2000 spectrophotometer (Hitachi®). Then the cells were used to make cell banks in 
20% (v/v) glycerol, the 100μl aliquots were stored at - 80°C in 1.5ml microcentrifuge tubes. 
  
3.1.2 DH5α COMPETENT CELLS: 
The cells were grown up to the O.D.600nm 1-1.5 (as described in section 3.1.1) and were 
centrifuged at 4000g for 10min. Supernatants were discarded, and the pellets were 
resuspended in 2ml of filtered TSS buffer (attachment1) and incubated for 10min on ice. 
Then aliquots with 100μl were prepared and stored at - 80ºC in 1.5ml microcentrifuge tubes. 
 
3.1.3 PLASMID DNA pTRKH3: 
The backbone plasmid used in this work was the pTRKH3 (figure 7) which is a shuttle 
cloning vector for E. coli, Lactococcus, Enterococcus, Streptococcus and Lactobacillus. The 
replicon includes an E. coli p15A origin as medium copy number (30-40 copies of plasmid 
per cell) and an Enterococcus faecalis pAMβ1 origin, denominated high copy number (45-85 
copies in Gram-positive strains). The tetracycline resistance is only expressed in E. coli 
(which can be insertionally inactivated, having several sites of cloning), while the 
erythromycin resistance is expressed both in E. coli and in Gram-positive bacteria. It was 
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demonstrated in previous studies [45] [46], that cloning vector pTRKH3 can be transmissible 
to certain strains of LAB. Through, the direct cloning in LAB, the need arises to use an 
intermediate host E. coli. 
 
Figure 7 – Physical map of plasmid pTRKH3 and some restriction sites [46] 
3.1.4 TRANSFORMATION DH5 α WITH PLASMID.  
DH5α cells were transformed with the plasmid pTRKH3, by heat shock. This was 
performed by the addition of 40µl of the plasmid (if is mutated or 10µl if is original pDNA)  to 
the competent cells, for 30min on ice. The mixture was heated for 1min 30s at 42ºC and then 
chilled on ice for 2min followed by the addition of 1ml LB and incubation at 37ºC. Finally, 
cells were plated on selective LB agar medium supplemented with 10µg/ml, tetracycline and 
incubated at 37ºC, approximately for 24 hours. Subsequently, were made cell banks as 
described in section 3.1.1. Plasmid DNA was purified with High Pure Plasmid Isolation Kit 
(Roche) following manufacturer’s instructions. The pDNA obtained were eluted in 100μl 
elution buffer and stored at 4⁰C. 
 
3.1.5 DIGESTION pTRKH3  
In order to confirm the quality of the pDNA a digestion with Hind III restriction enzyme 
(restriction site A^AGCTT) (Promega) which cuts plasmid at two sites and produces two 
fragments 5265pb and 2501pb. Each digestion procedure consisted of 500ng of pDNA, 0.5μl 
of enzyme (10U/μl), 10 % of 10X Buffer B and filtered sterilized Milli-Q water to a determined 
final volume (10-15 μl). All mixtures were incubated for 2h at 37⁰C. After that a 1% agarose 
gel electrophoresis was run.  
Production of therapeutic plasmid DNA by Lactic Acid Bacteria 
12 
 
3.2 LACTIC ACID BACTERIA 
3.2.1 CELL GROWTH OPTIMIZATION: 
The LAB cells were anaerobically cultured on Man Rogosa and Sharp (MRS) medium at 
37ºC in case L. plantarum CCUG 61730 and at 30ºC for L. lactis LMG 19460 with gentle 
agitation at 100 rpm. LAB cells were grown in a pre-inoculum overnight at 37°C in 15ml 
falcon tubes containing 15ml of MRS medium (52g/L) from Panreac Cultimed (see 
attachment 2 for the composition) supplemented with 5μg/ml of erythromycin stock solution 
(150mg/ml), when containing the pTRKH3 vector, in an ARALAB orbital shaker model 
AGITORB 200.  
The next day, the pre inoculum was used to start a new culture, by the addition of these 
cells to a fresh medium up to O.D.600nm=0.1. The cells grew for additional 6 to 7 hours, until 
the end of exponential phase, and cell banks were made in 20% (v/v) glycerol. The 100μl 
aliquots were stored at - 80°C.The LAB cells cultures were tested small scale (cell growth in 
15ml falcon tubes containing 15ml of MRS medium) and at bench scale (cell growth in 500ml 
Erlenmeyer flask containing 300ml MRS medium). To perform alkaline lyses, the cells were 
grown in a 2 litters Erlenmeyer flak containing 1 litter of MRS medium. In order to 
characterize the growth of L. lactis LMG 19460 and L. plantarum CCUG 61730 at small scale 
and bench scale growth curves were determined. For this, the growth was initiated at 
O.D.600nm=0.1 in both cases, and from that, the O.D.600nm was measured every hour.  
 
3.2.2 COMPETENT CELLS  
This procedure was done with strains without native pDNA, to avoid some 
incompatibility. For the transformation of LAB we tested some protocols for making cells 
competent as described below.  
 
Method 1 – G-SGMRS: 
This protocol was adapted from [47]. The LAB cells were grown overnight at 30°C and 
37ºC, depending on the strain, in 15ml falcon tubes containing 15ml of MRS medium and 
0.5M sucrose, 2.5% glycine, and 0.5% glucose. The growth started with O.D.600nm=0.1, in an 
100ml Erlenmeyer flask containing 100ml of the same new fresh medium.  
The cells were grown until early and middle of exponential phase and the growth was 
stopped in ice and then cells were centrifuged for 10min at 4000g. Then, the cells were 
washed with 50ml of ice-cold wash solution (0.5M sucrose, 10% glycerol), and centrifuged 
for 15min at 6.000g, at 4ºC. Subsequently, the cells were washed twice. First, the cells were 
kept on ice for 15min  in 25ml of solution containing 0.5M sucrose, 10% glycerol, and 0.05M 
EDTA and centrifuged for 15min at 6.000g, at 4ºC. Then, cells were washed with 12.5ml of 
ice-cold wash solution and centrifuged for 20min at 6.000g, at 4ºC. Finally cells were 
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resuspended in 0.5ml of ice cold wash solution. Aliquots of 100 µl were made and cells were 
stored at – 80ºC.  
 
Method 2 – 10mM Dithiothreitol (DTT) and 100mM Lithium acetate (LiAc) 
This protocol was done according to a modification of [46]. The LAB cells were growth 
overnight (as described in method 1) only with MRS medium. The new growth started with 
O.D.600nm=0.1 in a 15ml falcon tube containing 15ml of a same new fresh medium. After 
reaching the corresponding O.D.600nm (see attachment 3, table 9 with the conditions) the LAB 
cells were harvested in order to have 109 cells and centrifuged. The cells pellet following the 
pretreatment with LiAc and DTT was as follows: 109 cells were suspended at room 
temperature for 30min in 8ml of 100mM LiAc, 10mM DTT, 0.6M sucrose, and 10mM Tris-
HCl, pH 7.5. Following treatment, the cells were centrifuged for 10min at 4000g, at 4ºC and 
washed for 4 times with ice cold Milli-Q water and following the electroporation. In this 
method, electroporation was performed with fresh cells and was not made cell banks.  
 
Method 3 - 0.7 M Sodium Chloride (NaCl) 
This protocol was adapted from [48]. The LAB cells were grown overnight as described 
in method 1 only with MRS medium. The new growth started with O.D.600nm=0.1, in a 100ml 
of Erlenmeyer flask containing 100ml of a same new fresh medium supplemented with 0.7M 
NaCl. The cells were grown until early and middle of exponential phase, the growth was 
stopped on ice and then was centrifuged for 10min at 4000g, at 4ºC.  Thereafter, the cells 
were washed for 4 times with ice cold Milli-Q water and aliquots of 100µl were made with 
20% glycerol which were stored at – 80ºC. In table 3 (next section) is shown the O.D.600nm 
they reached and the cell number used for electroporation producing transformants.  
 
Method 4 - 8% Glycine 
This protocol was adapted from [49] [50] [51]. The L. plantarum CCUG 61730 cells 
following the same procedure of Method 3 NaCl. By medium of the competent cells was 
added 8% glycine. The L. plantarum CCUG 61730 were harvested (see attachment 3 and 
table 10) and centrifuged at the same conditions. The cells were washed for four times with 
ice cold Milli-Q water and cells bank was made at the same conditions.  
 
3.2.3 ELECTROPORATION OF L. lACTIS LMG 19460 AND L. pLANTARUM CCUG 61730 
Electroporation was optimized according to [46] [47] [51].The electroporation cuvettes 
were maintained 30min on ice before electroporation. The cell number was calculated 
according to Jones, S., et al [52], [53] (O.D.600nm = 0.1 or 7 x 10
7 CFU). The number of cells, 
the amount of pDNA and electrical pulse used in the methods (G-SGMRS, DTT / LiAc and 
8% Glycine) are shown with more detail in attachment 3. Here is described the conditions in 
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the NaCl method produced L. Lactis LMG 19460 transformants. In the NaCl method, 
electroporation was performed taking account the number of cells (as shown in table 3) using 
an electroporator with pulse controller (BTX ECM 399).  In some cases, was required add 2 
or 4 frozen aliquots and centrifuge the cells in order to be concentrated in a volume of 100µl. 
Electroporation was performed by a single pulse at 2-500V, 200 Ω, and 25 µF (pulse length 
ranged of 4.6 ms to 4.8 ms), in 2 mm electroporation cuvettes, using 1000ng of purified 
plasmid DNA. The cell suspension was diluted immediately by the addition of 1ml MRS and 
incubated for 3 hours at 30ºC or 37ºC (depending on the strain) without agitation. After the 
expression period, cells were plated onto MRS agar 2% supplemented with erythromycin (5 
µg/ml), and incubated for 72h for selection of transformants. Appropriate controls were made 
omitting pDNA or the electric pulse. Transformation was confirmed then by colony PCR. Cell 
banks were made and pDNA purification was done by nucleospin plasmid (Macherey Nagel 
Bioanalysis). The plasmid extracted was digested with Hind III (as shown in section 3.1.5).  
 
Table 3 - Cell number used in electrotransformation with NaCl method 
Strains O.D. 
600nm 
Cell concentration in 
frozen aliquots 
Number of cells used in 
electroporation  
Variation in 
electric pulse 
L. lactis 
LMG 19460 
0.63 2.94 x 10
9
 cells in 100 µl 
5.89 x 10
9 
CFU
  
and 
1.17 x 10
10 
CFU 
2 -500 V 
0.43 2 x 10
9
 cells in 100 µl 
4 x 10
9 
CFU  and 
8 x 10
9 
CFU 
2-500V 
L. 
plantarum 
CCUG 
61730 
2.16 9.97 x 10
9
 cells in 100 µl  
9.97 x 10
9 
CFU and 
1.994 x 10
10 
CFU 
2-500 V and 2x 
2-500 V 
2.16 9.97 x 10
9
 cells in 100 µl 
9.97 x 10
9
 CFU and 
1.994 x 10
10 
CFU 
2x 2-500 V and 
3x 2-500 V 
 
3.3 CONSTRUCTION OF pTRKH3 IN SILICO 
In order to construct the ribosome binding site (RBS) it was used the ApE® software. 
The RBS is a sequence found in prokaryotic mRNAs and its denominated Shine 
Dalgarno sequence. The Ribosome binds to the RBS and begins the translation at the start 
codon (ATG). The choice of RBS will affect protein expression levels. In order to produce an 
increased number of plasmid copies, it was tested two different RBS using the Anderson 
RBS library [39]. Thus far, the RBS library has not been experimentally characterized. The 
Anderson library was used to predict and design a two putatively stronger RBS sequences to 
replace the wild-type present in pAMβ1 origin of pTRKH3.  
 
3.3.1 SITE DIRECTED MUTAGENESIS  
For site directed mutagenesis it is necessary, that the mutagenic primer has high 
homology to the DNA strand which will be synthesized. The PCR Primers were designed 
using QuikChange Primer Design [54], and the sequences are in the attachment 4. Table 4 
shows the strategy adopted in the construction of primers to switch the RBS. 
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Table 4 - Sequences RBS 
 
 
 
 
The commercial kit Novagen® KOD Hot Start DNA Polymerase and the Thermo Hybaid 
Px2 thermocycler were used for the site directed mutagenesis. Each reaction mixture of 50µl 
contains 50ng of template pDNA, 1µl of KOD HotStart DNA polymerase (1U/µl), 4.5µl MgSO4 
(25mM stock concentration), 5µl Buffer KOD (10X concentrated), 10µl dNTP’s (2mM stock 
concentration),10 pmol each of forward and reverse primers and PCR grade water to obtain 
the final volume. The program used is shown in attachment 5. At the end of the PCR reaction 
was added to the mixture 1µl of the enzyme DpnI. The template DNA is methylated, and thus 
susceptible to DpnI digestion. The modified plasmids were used to transform to DH5α cells, 
where plasmid nicks are repaired and amplification occurs. Plasmid DNA proceeded to be 
purified with High Pure Plasmid Isolation Kit (Roche). To confirm the plasmid quality a 
digestion was made with Hind III restriction enzyme (as shown in section 3.1.5). The 
fragments obtained were run in a gel with 1% of agarose. The confirmation of the 
mutagenesis was made by sequencing by Stabvida.  
 
3.3.2 QUANTITATIVE REAL-TIME PCR ASSAY 
The quantification of plasmid copy number in L. lactis LMG 19460 was performed with 
the Roche LightCyclerTM detection system using the FastStart DNA Master SYBR Green I 
kitTM. The detection of pDNA was performed by amplification of a 190 bp sequence from the 
erm gene, the selective mark for erythromycin resistance (Forward primer: 5’ - CCA TGC 
GTC TGA CAT CTA TCT G - 3’ Reverse primer: 5’ – CTG TGG TAT GGC GGG TAA GT – 
3’). The L. lactis LMG 19460 cells necessary for RT-PCR were grown up to O.D.600nm = 1 as 
previously described. Cells where harvested, diluted in 100 µl and stored at -20ºC. The same 
amounts of cells (5 x 104) were used in all experiments including the pDNA standard curve.  
Plasmid DNA for standard curve was extracted from E. coli DH5α according to the Roche 
Miniprep Kit protocol. Serial five folds dilutions (1pg, 10pg, 100pg, 1000pg, 10000pg per 
capillary) of plasmid were conducted in triplicates to establish the standard curve. The CT 
values were used to calculate a linear regression line by plotting the logarithm of template 
concentration (X-axis) versus the corresponding threshold cycle (Y-axis), (as shown in 
attachment 8). 
Each 20µl of reaction mixture volume contained 2µl of the 10x SYBR Green mixture, 1µl 
of each primer (10µM final concentration), 1.6µl of MgCl2 (3mM final concentration), 2µl of 
sample and the remaining volume was fulfilled by PCR grade water. Determination of pDNA 
Original  RBS sequence  GTG GA GTT 
RBS 4  
One pair of primers to switch 4 nucleotides GGG GA CAA 
RBS 5   
One pair of primers to switch 3 nucleotides CAG GA CCC 
One pair of primers to switch 2 nucleotides CAG GA CCC 
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concentration in the L. lactis LMG 19460 cells was done in triplicate, for each analysis and 
performed by adding in each capillary was 2μl with 5 x 104 of these cells, 2μl of PCR grade 
water, and 16μl of the PCR reaction mixture. Reactions were incubated at 95ºC for 10min to 
activate FastStart DNA polymerase and lyse cells, followed by the amplification step 
consisting of 30 cycles of 10s at 95ºC, 5s at 56.9ºC and 7s at 72ºC, [55] reactions were kept 
at 70ºC for 30s, while fluorescence signal was continually monitored, for melting curve 
analysis. The final cycle, was a cooling step at 40ºC, 30s. Standard curves obtained in the 
reaction provide the relation between plasmid copy number and the CT, a relative 
quantification method.The calculations to obtain the number of copies were based on the 
calibration curve, by finding the log of the concentration, thus, knowing the concentration of 
pDNA and its mass. Therefore, allowed knowing the number of moles and molecules. The 
number of copies is obtained by dividing the number of molecules for the number of cells in 
the reaction (5 x 104 cells). 
 
3.3.3 COLONY PCR  
A PCR colony analysis was done to confirm cell transformation with pTRKH3. The pDNA 
was amplified for erm gene. The transformed colonies were picked into an eppendorf tube 
contain 70µl the Milli-Q water autoclaved and filtered (filter 0.1 µm). The 50µl of this volume 
was incubated at 99ºC for 5min to burst through the cells, the remaining 20µl were plated of 
positive PCR products. After the heat treatment, the cells were centrifuged at 11.000g for 
1min and 10µl of the supernatant (containing pDNA) were used to add to PCR reaction. The 
negative control was performed with L. lactis LMG 19460 cells without pDNA. 
The commercial kit used for amplification was NovaTaqTM Hot Start Master Mix kit – 
Novagen. Each reaction mixture of 50µl contains 10µl of pDNA, 25µl of Master Mix, 0.5µl 
(10µM stock concentration) each of forward and reverse primers and PCR grade water to 
obtain the final volume. The products of PCR reaction were run in a 1% agarose gel 
electrophoresis.  
 
4. PLASMID PRIMARY ISOLATION 
4.1 ALKALINE LYSIS  
L. lactis LMG 19760 cells harboring pTRKH3 plasmid, previously stored at -80ºC were 
cultivated overnight as described in section 3.2.1. The next day, these cells were used to 
inoculate a 100ml Erlenmeyer flask containing 100ml of fresh medium, with a starting 
O.D.600nm of 0.1. After 8 hours, these cells were transferred to a 2L Erlenmeyer flask with 1L 
of MRS medium, supplemented with 5µg/ml of erythromycin. These cells were grown 
overnight (for 12 hours) at 30⁰C and 100rpm until the early stationary phase, corresponding 
to an O.D.600nm =1.20-1.40. In order to collect the cells, the culture was centrifuged at 6000g 
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for 15min at 4⁰C. After centrifugation, the supernatant was discarded and the cell pellet was 
resuspended in buffer P1 (50mM glucose, 25mM Tris-HCl, 10mM EDTA, pH 8.0), using 
vortex. Filtrated stock of Lysozyme with concentration 10mg/ml was added to buffer P1. The 
required volumes of P1 were calculated with the previously measured O.D.600nm of the cell 
culture and following equation. The volume of P2 (0.2M NaOH, 1% (w/v) SDS) and P3 (5M 
potassium acetate, 6.8M glacial acetic acid) solutions, was the same volume of P1. 
 
   
                  
  
 
Where Vp is the volume of “P” solutions and Vculture is the volume of culture to be used. 
Alkaline lysis was performed by adding the P2 solution, followed by an incubation of 10min at 
room temperature. The P3 solution was added followed by gentle homogenization. To 
precipitate genomic DNA, the mixture was left on ice for 10min. The lysate was centrifuged at 
20.000g for 30min, at 4⁰C, in a Sorvall RC6 centrifuge with a SS-34 rotor, in order to remove 
genomic DNA, proteins and cell debris. The supernatant was placed in new tubes and 
centrifuged with the same settings as before to ensure complete removal of cell debris. 
 
4.2 CONCENTRATION AND CLARIFICATION 
In order to precipitate pDNA a previously calculated volume (70% volume of the lysate 
volume) of isopropanol (100% v/v) was added to the lysate, followed by careful and gentle 
homogenization and a static incubation for 2 hours at -20ºC for precipitation. The mixture 
was centrifuged for 30 min at 4⁰C at 20.000g and the supernatant was discharged. The 
pellets were left to dry overnight. The pellets were dissolved in 1000µl of Tris-HCl (10mM, pH 
8.0). The resulting solution was placed in eppendorf tubes with ammonium sulfate (taking 
into account that 500µl of Tris correspond 0.165 g of added ammonium sulfate). This mixture 
was homogenized and left on ice for 15min to allow removal of some impurities (proteins) by 
precipitation. The samples were centrifuged in an Eppendorf bench-top Centrifuge 5417 R 
with a rotor F45-30-11 at 18.000g and 4⁰C for 30min and the supernatant transferred to a 
new eppendorf tube. Samples were immediately processed in ÄKTA 100 purify system.  
 
4.3 HYDROPHOBIC INTERACTION CHROMATOGRAPHY (HIC) IN ÄKTA 100 PURIFIER 
SYSTEM 
Previously prepared Bio-Rad Econ-Pac columns, packed with 10cm height hydrophobic 
interaction resin, Phenyl SepharoseTM 6 Fast Flow was purchased from GE Healthcare (Bio-
Rad). The column was connected to an ÄKTA purifier system. Before chromatographic 
procedures, the columns were always washed with 30ml of Milli-Q water and equilibrated 
with 30ml of 1.5M ammonium sulfate (in 10mM tris-HCl pH 8.0). The standard purification 
Equation 1  
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protocol used to purify the plasmid DNA was based on [56] and the instrument used was 
ÄKTA GE Healthcare. A sample of 1ml of pDNA was injected in the column and isocratic 
elution was performed with 30ml of 1.5M ammonium sulfate (in 10mM Tris-HCl pH 8.0), with 
recovery of 1.5ml aliquots of flowthrough pDNA fractions. The remaining more hydrophobic 
molecules (RNA, genomic DNA, denatured pDNA) were eluted by injection of 30ml of 10mM 
Tris-HCl pH 8.0. The column was washed with 30ml of Milli-Q water and stored with 30ml of 
PBS and 0.05% sodium azide. Relevant chromatographic fractions, for both flowthrough and 
eluted peaks were analysed by electrophoresis using 1% of agarose gel. The samples 
recovered from the procedure, (free RNA) were selected for concentration and diafiltration.  
 
4.4 DIAFILTRATION - AMICON®   
pDNA was purified from ammonium sulfate using the Amicon® ultra millipore 30 KDa 
membranes. The fractions selected were free of RNA and were concentrated. To 2ml of 
sample volume was put in the Amicon® and centrifuge 15min at 4000g, afterwards and the 
flow is discharged. The first permeate is again placed for filtration. The process is repeated 
by placing 2ml of the sample and centrifuged (discharged flow through) until no remaining 
sample to elute. The diafiltration step was performed by adding 2ml Milli-Q water in the same 
volume present initially, followed by a centrifugation step using the same settings as before. 
Recovery of concentrated pDNA was achieved by turning the Amicon® upside down and 
eluted in 100µl of Milli-Q water, centrifuging it again under the same conditions. The final 
concentration of pDNA was measured in NanoDrop spectrophotometer at 260nm. A digestion 
was made as described in section 3.1.5.  
 
5. RESULTS AND DISCUSSION  
5.1 OPTIMIZATION OF THE GROWTH  OF  LAB  AT SMALL SCALE AND BENCH SCALE 
In order to analyse the growth of LAB cells, the respective cell growth curves at bench 
scale and small scale with or without pDNA were obtained. It is known that there are some 
factors which affect the growth of microorganisms, such as, the temperature, pH, agitation, 
available oxygen concentration, among others. In this case, these strains are anaerobic 
(although they are aerotolerant), grow with low agitation (100 rpm) and controlled pH of 
approximately 6.2 
It was also verified for these strains that sodium acetate (5g/l) and Tween 80 (1.0g /l) are 
essential to their growth (depending on trademarks if containing or not). The figure 8 shows 
the growth curve in falcon tubes and Erlenmeyer flask for these strains. Growth curves were 
performed with two Erlenmeyer flask and two falcon tubes, such that the last Erlenmeyer 
flask and falcon was 12 hours delayed in relation to the first. Thus, it was possible to take 
more points during the growth. 
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In all strains it was observed that the stationary phase can be maintained for a long time 
(figure 9), in which biochemical alterations may occur. Although the O.D.600nm is the same 
during this long stationary phase the physiological state is very different and that could affect 
pDNA production. At both small scale and bench scale, there were no significant differences 
in maximum O.D.600nm they reached. The exponential phase lasts approximately for 4 hours 
for L. lactis LMG 19460 and 6 hours for L. plantarum CCUG 61730. For L. lactis LMG19460 
with pTRKH3 lasts 6 hours, observing slower growth. L. lactis LMG 19460 cells without 
plasmid reach O.D.600nm = 3 and O.D.600nm = 1.60 with plasmid. The L. plantarum CCUG 
61730 cells achieve much higher O.D.600nm= 10. 
The figure 9 shows the specific growth rates for these strains in small scale and bench 
scale. The maximum specific growth rate (µmax) for both strains was obtained by applying a 
linear regression to the values in exponential phase. A Napierian logarithm is applied to 
these values and the maximum specific growth corresponds to the slope of the obtained 
equation. The L. lactis LMG 
19460 transformed cells, 
showed a slight decrease 
in specific growth rate. It is 
known, that plasmids may 
bring a higher metabolic 
burden to the cell and are 
likely to reduce the growth 
rate of the host cell [57]. 
This happens because 
cells harboring plasmid 
require more energy and nutrient to synthesize more DNA, mRNA and protein than the 
plasmid free cells [58]. 
Figure 8 - Growth curve of L. lactis LMG 19460 and L. plantarum CCUG 61730 harbouring or not pTRKH3 
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Figure 9 - Specific growth rate of L. lactis LMG 19460 and L. 
plantarum CCUG 61730 
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This can be seen with the slight decrease in the optical density of L. lactis LMG 19760 
cells, in part due to the sequestration of cellular resources for plasmid replication. The 
decrease in specific growth rate depends in part on strain, the copy number of pDNA and the 
nature of the cloning insert. As well as conditions of cell growth and the high levels of oxygen 
may affect your metabolism [59]. It can be verified at small scale and bench scale, that the 
growth rate did not affected significantly. The maximum growth rate, for strain L. plantarum 
CCUG 61730 was 0.48 h-1, for L. lactis LMG 19460 was 0.38 h-1 and L. lactis LMG 19460 
with pTRKH3, was 0.23 h-1. 
 
5.2 CONSTRUCTIONS OF SEQUENCES OF RBSs 
As described above, the choice of RBS was performed using the Anderson library. 
According to the prediction of this library, both RBS 4 and RBS 5 are described as being 
stronger for the expression proteins in E. coli. However, there may be differences in LAB for 
expression of REP D and REP E which may or not result in an increased number of copies of 
pDNA. The figure 10 shows the sequence of the RBS, as well as the codon upstream and 
downstream and the translation start codon. A few approaches have already been tested at 
the pAMβ1 origin in order to increase the copy number. It was shown, that inactivation in the 
copy control region (CopF), led to an increase in the number of copies [37].  
  
 
 
                                    Figure 10 - Modification of RBS sequences in pTRKH3 
It was also verified that introduction of PCT or TDE mutations in a pDNA, which lacks the 
CopF repressor, does not cause a further increase in copy number. This may be due to a 
limiting factor for plasmid replication [31]. In another study was inserted the spac-I promoter 
upstream of ORF E in the plasmid pAMβ1spac replicated efficiently resulting in about 100 
plasmids copies/cell in Bacillus subtilis [34]. 
 Thus, in order to test another approach, it was chosen to switch the original RBS 
sequence of pAMβ1. The modification to RBS 4 was successful however, the complete 
sequence of the RBS 5 (CAG-GA-CCC), has not been totally achieved. As mentioned 
before, there are some factors that influence the efficiency of translation. Therefore, the rate 
at protein synthesis can be different, compared to original sequence (GTG-GA-GTT). It may 
occur a transient pausing in the translation of the protein sequence that are influenced by the 
GAAG GTG GA GTT  TGT ATG 
   
Original RBS sequence 
GAAG GGG GA CAA  TGT ATG 
    
RBS 4 
GAAG CTG GA GCC  TGT ATG 
 
RBS 5 incomplete 
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messenger RNA [42]. Thus, the same protein can be translated at different rates. It was also 
described that RBS with purine rich sequences A's and G's close to the Shine Dalgarno 
sequence will lead to high rates of translation initiation [39] as can be observed by the 
sequence of the switch RBS 4 (GGG-GA-CAA). Then, will be shown the quantification of 
RBS 4 in some colonies compared to original RBS. 
 
5.3 OPTIMIZATION OF LAB TRANSFORMATION 
Plasmid incompatibility may occur if the cells to be transformed already harbour a native 
plasmid. The native plasmid and the transformed plasmid might compete for components 
required for their replication. Thus the weaker vector would become unstable or even 
disappear [19]. Therefore, the strains used in this work were devoid of native plasmids. 
There are several techniques for cell transformation but among them, electroporation 
provides the highest efficiency. This is a method that has been successfully employed with a 
number of bacterial species [50]. The use of a cell wall weakening agent during growth may 
be advantageous, because stimulate electrocompetence in various bacteria [49]. Incubation 
with high concentration of sucrose it’s known to cause a weakening of the cell wall in several 
bacteria. Different protocols for electrotransformation, previously described in section 3.2.2 
were tested. It was verified that the strain L. lactis LMG19460 didn’t grow when using the 
medium of method 1 (G-SGMRS) due to the fact that glycine at this concentration of 2.5% 
inhibits the formation of cell and affects the growth, in such a way that cells may not 
complete cellular division. The L. plantarum CCUG 61730 strain grew up to O.D.600nm = 1.55 
and O.D.600nm = 0.57. However, the transformation was not achieved, even varying several 
parameters, such as the intensity of the shock (either with one pulse or two pulses of 2-
500V) and the amount of pDNA (100 ng, 500 ng and 1000 ng). It would be expected that the 
growth medium could be effective in making cells more competent. However, the 2.5 % of 
glycine and 0.5M of sucrose (increased osmotic pressure) induced cell wall weakening 
strategy was shown too much aggressive for L. lactis LMG 19460 cells preventing their 
growth and ineffective for the transformation of L. plantarum CCUG 61730 cells. 
The second method used was based in a pretreatment of the cells with LiAc and DTT 
before electroporation. These chemical components (commonly used for transformation of 
yeast) are reported to enhance the efficiency of transformation [46]. It was demonstrated that 
the transformation efficiency was higher with these two compounds together, compared 
omitting one of them [46]. The LAB cells were harvested during the exponential phase and 
the number of cells (109 cells) was controlled as suggested. It was verified that this process 
did not result for these strains. A test with more cells or an increased electric pulse should be 
performed.  
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In Method 3 a simple protocol was tested, involving high concentration of NaCl in the 
growth medium, acting also as a cell-wall weakening agent. The L. lactis LMG 19460 and L. 
plantarum CCUG 61730 cells were grown at a NaCl concentration of 0.7M. The growth in 
0.9M NaCl was also tested, but at this concentration the strain L. lactis LMG 19460 did not 
grow, perhaps because of its osmosensitivity. The L. plantarum CCUG 61730 cells were 
grown up to O.D.600nm= 0.90, with the same conditions described in table 3 (section 3.2.3). It 
was verified the failure to obtain transformants. It was also attempted another approach to 
this protocol, according to the publication [49]. After recovery, the cells were inoculated into a 
liquid medium (MRS) with sublethal concentration of erythromycin (0.5 µg/ml) overnight. 
Afterwards, the cellular suspension was plated into MRS agar with 5 µg/ml erythromycin.  
Although this approach is described as an alternative for transforming L. plantarum and 
some other species, for our tested strains give no colonies containing pTRKH3.  
Table 5 shows the O.D.600nm and cell concentrations tested for electroporation of both 
strains. For the tested conditions, only the L. lactis LMG 19460 strain showed transformants.  
Table 5: Results of electrotransformation 
Strains 
O.D. 
600nm 
Number of cells used in 
electroporation 
Number of Transformants / µg 
pDNA 
L. lactis 
LMG 
19460 
0.44 8.5 x10
9  
CFU with pTRKH3 wt 3 
0.63 
5.89 x10
9  
CFU with pTRKH3-RBS4 3 
1.17 x10
10  
CFU with pTRKH3-RBS 4 16 
0.43 
4 x10
9 
CFU with pTRKH3-RBS 4 200 
8 x10
9
 CFU
 
with pTRKH3-RBS 4 0 
L. 
plantarum 
CCUG 
61730 
2.16 
9.97 x10
9
 CFU with pTRKH3 wt 0 
1.99 x10
10 
CFU
 
with pTRKH3 wt 0 
2.16 
9.97 x10
9 
CFU with pTRKH3-RBS 4 0 
1.99 x10
10
 CFU
 
with pTRKH3-RBS 4 0 
 
In order, to verify the influence of the growth phase in the electrotransformation, L. lactis 
LMG19460 cells were harvested at an O.D.600nm= 0.43 (early exponential phase) and 
O.D.600nm= 0.63 (middle exponential phase). In general, many factors can influence the 
transformation efficiency. Some are linked to the plasmid origin, size, replication 
mechanisms, whereas others are linked to the characteristics of the strains used like the 
growth phase of the cells being transformed [48] [50] and effect of agents which weaken the 
cell wall. It was demonstrated that cells harvested in the middle of exponential growth phase 
show higher transformation efficiency, when compared to cells recovered in the early 
exponential phase [50]. 
 By the analyses of the results, it is obtained that there is a variation in the number of 
transformants that is dependent on the growth phase of the L. lactis LMG 19460 cells. In 
turn, it was reported that too close O.D.600nm (0.45-0.50) may lead to differences in the 
number of transformants [50]. However, the electrotransformation with pTRKH3 carrying the 
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mutation produced more colonies. It was verified more transformant colonies were achieve at 
an O.D.600nm = 0.43. This method proved to be easy, simple and effective for L. lactis LMG 
19460. It was described as a better method when compared to the other cell wall weakening 
agents based protocols (lysozyme, glycine or penicillin) [48]. 
Finally was tested a method 4, where the cells was increased the concentration of 
glycine up to 8% to grow competent cells. As reported, the number of transformants 
increases with increasing concentration of glycine [49]. According to the authors, high 
transformation efficiency was obtained with addition of 8% of glycine to growth medium. In 
this method, it was decided to not test L. lactis LMG 19460 cells, because the glycine (in high 
concentration) in growth medium inhibited cell growth. The L. plantarum CCUG 61730 strain 
grew up to O.D.600nm=0.38 and the electroporation was performed as described in attachment 
3, table 10, varying cell number and electric pulse. However, this method has proved 
ineffective to obtain transformant colonies. With this concentration the cell growth seems to 
have been affected. Thus, the cell growth with a lower glycine concentration of 4% for 
example, could be tested. 
 In the tested methods it was also observed that depending on the growth medium of 
competence cells, growth may be affected, which is reflected in O.D.600nm that can reach the 
cells. It was described that different parameters for the electroporation varies between strains 
[60]. The number of cells electroporated is important in obtaining the maximum number of 
transformants [60] and is recommended to use cell concentration in the range of 2 x108 to 5 x 
109 CFU/ml [61]. It was also reported an increase in transformation efficiency with stationary 
phase cells at high cell concentrations (5 x 1010 CFU/ml) [61]. In another study  It was also 
demonstrated that the number of transformants was proportional to the pDNA concentrations 
[62] and It was obtained with an expression period of 3 hour best results [60]. The electric 
pulse also have the impact in the number of transformants obtained. At lower voltage, longer 
pulses are necessary as well as at the highest voltage, only short pulses should be used 
[62]. As was demonstrated an inter-relation between all this factors, it can influence 
transformation efficiency.   
 
5.4 QUANTIFICATION OF RELATIVE PLASMID COPY NUMBER 
The relative quantification copy number of plasmid pTRKH3 was performed by using real 
time PCR (RT-PCR), based on the work of Carapuça et al. [55].Until the date of conclusion 
of this work, it was not quantified pDNA copy number of the L. lactis LMGpTRKH3-RBS 5. It 
will be done subsequently. Attachment 5 and 6 show all experiments.  
The L. lactis LMG 19460 cells were harvested at the end of exponential growth phase 
O.D.600nm=1.01 ± 0.14 (A ± SD), where there is no wide variation in the physiological behavior 
of the cell and consequently in the number of plasmid copies per cell. 
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To evaluate the relative copy number of pTRKH3, three colonies (3 different 
transformants) of L. lactis LMG19460 with pTRKH3 wt containing the original RBS, (table 6) 
and 8 different transformants L. lactis LMG19460 with pTRKH3-RBS4 (table 6). The figure 11 
shows the average of all colonies.  
 
 
 
 
 
 
 
 
 
 
 
The number of copies of the original plasmid pTRKH3 wt (containing the non-modified 
RBS) varies between (114 and 276 copies per cell), as determined by RT-PCR. Several 
assays were performed to quantify and also to test the effect of the modifications in the RBS 
sequence in the plasmid copy number as recommend by [63]. It can thus verify for pTRKH3-
RBS4, four colonies which harbor large amounts of pDNA which contain (between 998 and 
2490 copies per cell). For these colonies the increase was between 367% and 1065%. Other 
4 colonies where there is no wide variation compared to pDNA wt containing (between 149 
and 290). These colonies still showed an increased between 34% and 36%. It has been 
found always a number of copies similar for both experiments with pTRKH3 wt. 
Such variation in copy number between colonies (4 to 11), may be due to the ability of 
some colonies have for supporting a higher number of copies of pDNA. Some colonies may 
be more metabolically resistant to maintain a high copy number of pDNA. During cell growth 
it may occurs a significant decrease in plasmid copy number. In order to estimate, if there is 
a large variation other experiments could be considered. For example, the middle and the 
end of the exponential phase and early stationary phase could be analyzed. Plasmids with 
high pDNA copy number, imposes a higher metabolic load to the cell [64]. Thus, there may 
be some structural change as a result of a physical modification [65]. This can be verified in 
the colonies 5, 7, 8 and 9 seem to produce large amounts of pDNA (figure 11). The figure 12 
shows all growths performed of L.lactis LMG 19460 with pTRKH3 wt and pTRKH3-RBS 4. 
Figure 11 - Estimated copy number of pTRKH3 for different colonies. Colonies 1-3: LMG19460 cells 
electroporated with pTRKH3 wt. Colonies 4-11: LMG19460 cells electroporated with pTRKH3-RBS4. Bar chart 
shows the averages of each colony of several assays. The error bars represent the standard error (for each cell 
bank). 
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The average of copy number of several growths is high for colonies 5, 7, 8 and 9 
compared with the other colonies. It may occur, throughout the generations a gradual loss of 
the pDNA [57] as a result of high copy number of pDNA. During the exponential phase 
wherein the metabolic activity of the cell is more intense, pDNA may be a higher burden. 
Factors such as, composition of medium and rate of cell growth, can also affect the copy 
number of plasmid [57] [65].  
It is described in some cases, that there is some variation in the production of 
recombinant proteins in E. coli clones. Thus, it is possible to exist clones of L. lactis LMG 
19460 producing more copies of pDNA. The relative value for the number of copies of 
pTRKH3 calculated may be overestimated. This occurs for both LMG/pTRKH3 wt as for 
LMG/pTRKH3 – RBS 4. A significant increased in fluorescence (SYBR Green dye) was 
observed early, as a result of the higher copy number of the pDNA. In this method it was 
used the SYBR Green dye. This dye binds to any double-stranded DNA and it can also bind 
to nonspecific double-stranded DNA sequences that could generate false positive signals 
[66]. Each sample analyzed in the RT-PCR assays, consisting of the same number of cells, 
resulted in a CT value (cycle threshold), which corresponds to the number of amplification 
cycles necessary for the fluorescent signal to surpass the background level (threshold). By 
analysis of the melting curves, it seems that nonspecific product was not formed. The PCR 
reactions were analyzed by the melting curves and by gel analysis. Therefore, there may be 
a nonspecific binding of primers, yielding a PCR product similar to specific fragment of 
expected size on gel. In order to overcome this, the number of cycles of RT-PCR can be 
lowered to 25. For an additional analysis it was extracted pDNA by miniprep (results are 
shown in the next section). Beside the methods used in this study, quantification by HPLC 
could be performed and for a more precise analysis, a digital PCR may be used.   
Figure 12 - Estimated copy number for various assays. Data displayed represents results from several 
independent assays with tree replicates from each colony. The red balls and blue triangles shows the average 
of all assays. The red X shows the total average. In attachment 6 and 7 can be verified the average Ct’s value of 
the total samples analyzed. Scatter plot it was obtained from R statistical computing software. 
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5.5 COMPLEMENTARY METHOD TO QUANTIFY COPY NUMBER OF pDNA BY 
MINIPREP 
In order to make a complementary analysis to RT-PCR, it were grown colonies 1 and 2 
of L. Lactis LMG/pTRKH3 wt, colony 5,7,8,9 (higher producers) of LMG / pTRKH3 - RBS 4 
and colony 10 of LMG / pTRKH3 - RBS 4. The growths were performed as described in 
Section 3.2.1 and followed the instructions of the kit protocol (Macherey Nagel Bioanalysis). 
The final concentration of pDNA was measured in NanoDrop at 260nm. The following table 7 
shows the final O.D.600nm, the mass of pDNA obtained and corresponding estimated number 
of copies of pDNA. 
Table 6 - Estimated number of copies of pTRKH3 by Miniprep 
Cells banks O.D.600nm 
Mass of pDNA 
after Miniprep 
Estimated number of 
copies of pDNA per cell 
Colony 1 LMG/pTRKH3 wt 0.86 13620 ng 177 
Colony 2 LMG/pTRKH3 wt 1.14 27180 ng 267 
Colony 5 LMG/pTRKH3 – RBS 4 1.20 25200 ng 252 
Colony 7 LMG/pTRKH3 – RBS 4 1.39 54960 ng 442 
Colony 8 LMG/pTRKH3 – RBS 4 1.10 30120 ng 306 
Colony 9 LMG/pTRKH3 – RBS 4 1.17 28800 ng 275 
Colony 9 LMG/pTRKH3 – RBS 4 1.03 46800 ng 508 
Colony 10 LMG/pTRKH3 – RBS 4 0.78 19800 ng 284  
Colony 10 LMG/pTRKH3 – RBS 4 0.99 28800 ng 325 
 
As previously described, it seems to be an increased number of copies of pTRKH3 – 
RBS 4. It is not certain that the process of lysis by miniprep is completely effective, as this 
method also presents some limitations. It may happen some saturation of the column during 
the purification and it may not elute all pDNA. The step of cell lysis may not be completely 
efficient, requiring for example more than 10mg/ml lysozyme concentrations.  It is described 
that the number of copies of vector pTRKH3 in streptococcal and lactococcal hosts varies 
between 45 and 85 copies per cell. A value higher than those was obtained by miniprep (± 
222) and by RT-PCR (± 214). Comparing the values of copy number of pTRKH3-RBS4, 
these results suggest that there is a higher number of copies in L. lactis LMG 19460.   
Moreover, it is known that depending on the strain of E. coli, the production of pDNA it can 
be vary, this may also happen to strains of LAB cells. Therefore, it was also found in a 
previous study [45], a large variation of the same promoter activity in different strains of LAB.  
 
5.6 CELL LYSES AND CHROMATOGRAPHY 
The alkaline lysis method is widely used for pDNA purification from E. coli. Therefore, 
alkaline lysis was the procedure of choice for the first step of pDNA recovery. The purification 
processes are extremely important, because there are many molecules (genomic DNA, RNA, 
proteins) that can contaminate the final solution of pDNA [2]. During the alkaline lysis there 
are some steps which require some care. The mixing is very important, to ensure the lysis of 
almost all cells in the population, since the surfactant will destabilize the cell wall’s integrity. 
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In addition to this, the mixing should be very gentle to avoid plasmid DNA to be affected by 
shear and  also which can be degraded at high pH values [67]. The next step was the 
isopropanol precipitation which is used to promote plasmid precipitation. In this work the 
isopropanol precipitation for 2 h at -20ºC yielded larger amounts of pDNA at the end of the 
purification than precipitation overnight at 4ºC. After this step, some contaminants such as 
RNA and proteins are still remaining. Therefore a precipitation step of these contaminants 
with 1.5M of ammonium sulfate, was performed. The following step, optimized for plasmid 
purification from E. coli, was hydrophobic interaction chromatography (HIC) using the ÄKTA 
100 purifier system.  
Before the performance of HIC, it is evident (by 1% agarose gel electrophoresis) the 
presence of RNA contaminating the pDNA sample (results not shown). HIC separates 
supercoiled (sc) pDNA from the more hydrophobic single-stranded nucleic acids, RNA, 
gDNA and endotoxins, [68] (if exploiting the differences in their behavior once exposed to 
hydrophobic ligands (Phenyl-sepharose resin)) in the chromatographic column. Other 
plasmid isoforms, such as open circular (oc) pDNA and linear pDNA, which are products of 
the degradation of sc pDNA, which can occur during even careful pDNA purification 
processes (due to non-optimal pH, temperature and several centrifugations), but are less 
efficient in promoting gene expression [68]. These unwanted conformations are caused by 
single strand nicking, which results in the relaxed form of sc pDNA, the oc pDNA, and 
double–strand nicking, by restriction endonucleases, which originates linear pDNA. HIC was 
started by injected the sample after ammonium sulfate clarification into the column 
connected in ÄKTA 100 purifier. The chromatogram shown in figure 13A indicates a low 
concentration of pDNA in the eluted fractions. Figure 13B shows pDNA isoforms of the 
samples collected from HIC from the original purification process. 
 
Figure 13 – A: HPLC Chromatogram of pDNA sample from the original purification procedure. B: 
Agarose gel electrophoresis 1% of the eluted fractions from a purification procedure. It is possible to 
detect a lower amount of pDNA. Lane M – Molecular-weight marker (NYZ DNA Ladder III, NYZTech). Lanes 
(2-15) – samples from the first run eluted. 
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The fractions which contained pDNA were collected and concentrated using the 
AMICON® 30 kDa membranes.The AMICON® 30kDa membranes are efficiency for 
desalting and concentrated the sample. Diafiltration, or ultrafiltration, achieves desalting or 
buffer exchange through the use of centrifugal force to drive small microsolutes through a 
porous membrane. The membrane does not allow macrosolutes (larger than the pore size) to 
pass through. Amicon Ultra devices incorporate a regenerated cellulose membrane to 
provide maximum sample recovery. The hydrophilic microstructure of membrane ensures the 
lowest possible adsorption of protein and other macromolecules, and the highest recovery of 
the sample. Samples of 100μl obtained AMICON were quantified in Nanodrop through 
spectrophotometry at 260 nm, the final amount eluted contained 11.2 µg.  
The quality of the purified pDNA solution and evaluation of the separation of plasmid 
from impurities was assessed through 1% agarose gel electrophoresis (results nor shown). 
In the end the final amount of pDNA was too low. Therefore, a tentative to increase the 
final pDNA yield was made by adding lysozyme to the lysis step. The rational was the fact 
that LAB are gram positive bacteria and lysozyme which hydrolyses the peptidoglycan is 
commonly used in methods for disruption of cell wall, of yeasts and gram positive bacteria. 
Comparing the fractions (figure 13A) and the area of peak in the chromatogram of the 
previous run, the addition of lysozyme, yielded much more plasmid (can be verified by 
absorbance pDNA pick 600mAU (figure 14A) compared to 50mAU).  
The purification procedure was completed using the AMICON membranes, to remove 
ammonium sulfate and to concentrate the fractions containing pDNA and no RNA (figure 14). 
The final amount of pDNA eluted after used AMICON was 368.14 µg. Quality of the purified 
pDNA was assessed by digestion and agarose gel electrophoresis (as shown in attachment 
10). Based on that, it is possible to provide for an increase of 3000 % pDNA with the addition 
of lysozyme.  
 
Figure 14 – A: Chromatogram from a purification procedure using lysozyme. B: Agarose gel analysis of 
the eluted fractions from a purification procedure with lysozyme. M – Ladder III NZYtech; Lines (2-13) – 
samples from the first run eluted. Lines (14-15) – samples from the second run eluted. 
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6. CONCLUSION 
Producing plasmids in LAB cells with a high copy number may not be easy. The LAB 
cells behave differently from E. coli where the production and purification methodologies are 
well established. In order to adapt and optimize all these techniques, to produce pDNA in 
LAB, the growth and the purification processes, require several adjustments. From the 
experiments performed in this work, it can be concluded that, the transformation of the LAB 
cells, is an important process. Some strains are more easily transformed than others for 
same the procedures. The method using NaCl was efficient for transformation of L. lactis 
LMG19460. It was also found that the amount of cells required for electrotransformation and 
the growth phase of cells, strongly influenced the transformation success.  The 
electrotransformation was successful from 4 x 109 to 1.17 x 1010 cells. However, the strain L. 
plantarum CCUG 61730 was unable to give transformants eventually to a cell wall that 
difficult pDNA uptake even changing some parameters. Additionally, this transformation 
failure may also be due to the active endA gene encoding endonuclease I. It was found that, 
the type strain Lactobacillus plantarum subsp plantarum ATCC 14917 has this gene [69]. To 
confirm that L. plantarum CCUG 61730 has this gene, PCR analysis is required. 
It was found that lysozyme 10 mg / ml added to the alkaline lysis buffer significantly 
increased the amount of pDNA (368 µg), comparing to what would happened if we didn’t use 
it (11 µg). However, in order to optimize this process higher concentrations of lysozyme (15 
and or 20 mg / ml) or increased incubation periods should be tested. Additionally as plasmid 
purification was performed with cells from one liter of culture of L. lactis LMG/pTRKH3-RBS 4 
it would be advantageous to increase the scale to produce more pDNA. 
The modified RBS 4 allowed an increase in plasmid copy number up to 332% fold if 
compared with the non-modified origin of replication present in pTRKH3. To complement this 
study, other colonies should be analyzed by RT-PCR. These pDNA of the high-producing 
clones was sequenced and it was confirmed the expected modified sequence. A HPLC 
analysis of the amount of pDNA produced by these strains is required in order to validate the 
amounts given by the RT-PCR or for a more precise analysis digital PCR may be used. 
This LAB host system may be a safer alternative for the development of DNA vaccines 
currently produced in E.coli. This new application will reinforce other potential applications of 
LAB for human health, as delivery vehicles and for the production of heterologous proteins. 
 
7. FUTURE PERSPECTIVES  
As mentioned before, this thesis was focused on the engineering of pTRKH3 to increase 
it’s copy number in lactic acid bacteria, and thus increment pDNA yield. Additionally, it was 
necessary to optimize LAB growth and the steps of electrotransformation and pDNA 
purification. There are thus still many processes that can be optimized in future work. First, 
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it’s needed to confirm that the endA gene is active in L. plantarum CCUG 61730, and thus 
would be interesting to knockout endA gene. It would be interesting to evaluate the effect of 
modified origins of replication of pTRKH3 in several LAB strains. Other approaches like 
promoter PDE replacement may be also tried in order to increase the copy number of 
pTRKH3.  
Optimizing the growth of cells with plasmid in a continuous or fed-batch bioreactor, once 
there are already some studies for these bacteria applied in the fermentation of food industry, 
but not in the production of DNA vaccines. On the other hand, several methods of cell 
disruption could be compared such as, microfluidization, bead milling, sonication and could 
be good alternatives as they are already being used in biopharmaceuticals and 
biotechnology processes. It is relevant to optimize the purification process in order to obtain 
grams of sc pDNA. There are other species and strains of LAB which may contain unknown 
types of plasmids and it would be interesting to characterize them because they may contain 
new origins replication. 
In the next future, the use of pTRHK3 as a DNA vaccine backbone with therapeutic 
cloning genes and produced in LAB could be used in animal trials. 
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ATTACHMENT 1 – TSS STOCK SOLUTION FOR DH5α COMPETENT CELLS 
To prepare TSS stock solution for DH5 α competent cells is necessary adding for 2 ml 
mixture: 20g/L LB; 5% DMSO; 50mM MgCl2; 10% PEG 8000 (v/v); ph 6.5. 
 
ATTACHMENT 2 – MRS BROTH PANREAC® CULTIMED 
Di-ammonium hydrogen citrate 2.0 g/l, Beef extract 8.0 g/l, Yeast extract 4.0 g/l, D (+) - 
Glucose 20.0 g/l, Magnesium sulfate 0.2 g/l, Manganese (II) sulfate 0.05 g/l, Bacteriological 
Peptone 10.0 g/l, Di-Potassium hydrogen phosphate 2.0 g/l, Sodium acetate 5.0 g/l, Tween 
80 1.0 g/l, pH6.2.  
 
ATTACHMENT 3 - OTHERS METHODS TESTED FOR ELECTROPORATION 
 
Table 7 - Electroporation conditions of method 1 - G-SGMRS 
Method G-SGMRS 
Cells O.D.600nm 
Cell Number and 
amount of pDNA 
Variation in 
electric Pulse 
L. plantarum CCUG 61730 
0.57 
1.11 x 10
9 
CFU in 40 µl 
and 500 ng pDNA 
2-500V and 2x 2-
500V 
2.22 x 10
9 
CFU in 80 µl 
and 100 ng pDNA 
2-500V 
1.55 
10
9 
CFU
 
in 100 µl and 
1000 ng pDNA 
2-000V and 2-500V 
10
9 
CFU
 
in 100 µl and 
500 ng pDNA 
2-500V 
 
 
Table 8 - Electroporation conditions of method 2 – DTT/LiAc 
Method DTT / LiAc 
Cells O.D.600nm 
Cell Number and 
amount of pDNA 
Variation in 
electric Pulse 
L. lactis LMG 19460 
0.63 
10
9 
CFU
 
in 100 µl and 
500 ng pDNA 
2-500 V 
1.20 
10
9 
CFU in 100 µl and 
1000 ng pDNA 
2-500 V 
L. Plantarum CCUG 61730 
1.27 
10
9 
CFU in 100 µl and 
1000 ng pDNA 
2-500 V 
0.51 
10
9 
CFU in 100 µl and 
500 ng pDNA 
2-500 V 
1.78 x 10
9 
CFU in 100 
µl and 1000 ng pDNA 
2-500 V 
 
 
 
Production of therapeutic plasmid DNA by Lactic Acid Bacteria 
36 
 
Table 9 - Electroporation conditions of method 4 – 8% Glycine 
Method 8% Glycine 
Cells O.D.600nm 
Cell Number and 
amount of pDNA 
Variation in 
electric Pulse 
L. plantarum CCUG 61730 0.35 
3.26 x 10
9 
CFU in 100 
µl and 1000 ng pDNA 
2-500V 
4.89 x 10
9 
CFU in 100 
µl
 
and 1000ng pDNA 
2 x 2-500V 
 
ATTACHMENT 4 - PRIMERS FOR SITE DIRECTED MUTAGENESIS 
Table 10 - Primers for site directed mutagenesis 
 Name Primers Length pb Tm 
RBS 
4 
Forward 
primer 
5’ – CGTTTGATTGCTTTTTTTGTATTCATTTATA 
GAAGGGGGACAATGTATGAATCATGATGAATGTAAAA 
CTTATATAAAA - 3’ 
79 77 
Reverse 
primer 
3’- TTTTATATAAGTTTTACATTCATCATGATTCATA 
CATTGTCCCCCTTCTATAAATGAATACAAAAAAA 
GCAATCAAACG - 5’ 
79 77 
RBS 
5 
Forward 
primer-F3 
5’ – TTTATATAAGTTTTACATTCATCATGATTCATACA 
GGCTCCAGCTTCTATAAATGAATACAAAAAAAGCAAT
CAAACG - 3’ 
78 78 
Reverse 
primer-R3 
5’ – CGTTTGATTGCTTTTTTTGTATTCATTTATAGAAG 
CTGGAGCCTGTATGAATCATGATGAATGTAAAACTTAT
ATAAA - 3’ 
78 78 
Forward 
primer-F2 
5’ – TTTACATTCATCATGATTCATACAGGGTCCTGCT 
TCTATAAATGAATACAAAAAAAG - 3’ 
57 73 
Reverse 
primer-R2 
3’ – CTTTTTTTGTATTCATTTATAGAAGCAGGACCCT 
GTATGAATCATGATGAATGTAAA - 5’ 
57 73 
 
ATTACHMENT 5 - PCR PROGRAME FOR SITE DIRECTED MUTAGENESIS   
Reactions were incubated at 95ºC for 3 min to activate HotStart DNA polymerase, followed 
by 30 cycles of 40s at 95ºC, 60s at 60ºC and 5min at 70ºC.  
 
ATTACHMENT 6 – ASSAYS LMG/pTRKH3 (wt) 
Table 11 - Assays for RT-PCR - Overview of all cells banks LMG/pTRKH3 wt 
 O.D.600nm 
Average 
Ct’s 
Copy number pDNA Average Standard error 
Cell bank 1 
1.11 
15.59 179.8 
231.8 
 
26.3 
 
15.11 250.4 
0.99 15.80 265.0 
Cell bank 2 
 
1.05 
15.72 165.2 
276.6 
 
85.6 
 
14.05 523.0 
15.05 262.3 
1.40 15.03 155.8 
Cell bank 3 
1.16 16.89 73.4 
90.2 16.6 
1 16.35 107.0 
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ATTACHMENT 7 - ASSAYS LMG/pTRKH3-RBS 4 
Table 12 - Assays for RT-PCR - Overview of all cells banks LMG/pTRKH3 RBS 4 
 O.D600nm 
Average 
Ct’s 
Copy number pDNA Average Standard error 
Cell bank 4 
1.07 
15.04 264.1 
285.4 29.9 
14.573 364.5 
14.9 291.0 
1.02 15.29 222.2 
Cell bank 5 
0.63 14.986 274.1 
1187.1 423.7 
1 14.967 277.8 
1.02 12.94 1125.0 
0.92 12.215 1855.3 
0.63 11.84 2403.2 
Cell bank 6 
1.04 16.23 116.2 
149.3 
33.1 
 1 15.577 182.4 
Cell bank 7 
1 
12.033 2103.1 
1710.2 
 
 
358.01 
 
 
11.77 2522.2 
0.99 
12.965 1105.8 
12.96 1109.6 
Cell bank 8 
0.97 
12.866 1183.9 
998.2 
 
100.0 
 
13.18 953.3 
1.01 
13.415 810.6 
12.76 1273.7 
1.09 13.29 769.7 
Cell bank 9 
0.78 
11.163 3834.3 
2490.9 
 
 
636.7 
 
 
11.165 3829.0 
1 
11.755 2548.4 
12.31 1735.6 
0.99 14.1 505.2 
Cell bank 10 
0.97 
14.526 376.6 
290.0 
 
38.8 
 
14.705 332.8 
1.03 15.18 239.8 
1.05 15.36 211.1 
Cell bank 11 
1.03 
15.513 190.6 
183.4 
 
21.52 
 
15.12 249.9 
1.25 15.69 168.7 
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ATTACHMENT 8 – CALIBRATION CURVE RT-PCT    
 
 
 
 
 
 
 
 
 
ATTACHMENT 9 - AGAROSE GEL 1% - RT-PCR REACTION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 – Confirmation in 1% agarose gel electrophoresis of plasmid pTRKH3 in RT-PCR reaction. A - 
Lanes (1-6) correspond to controls; Lanes (7-14) correspond to pTRKH3 calibration curve. B - Lanes (15-21) 
correspond to pTRKH3 calibration curve; Lanes (22-28) correspond to samples; M - Molecular weight marker 
NYZDNA ladder III (NYZTech). 
Figure 15 - Standard curve for the relative quantification of plasmid copy number, 
obtained using pDNA masses ranging from (1pg, 10pg, 100pg, 1000pg, 10000pg). Regression 
analysis is presented by r
2
 values. 
y = -3,3368x + 20,879 
R² = 0,9998 
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ATTACHMENT 10 – DIGESTION OF PTRKH3 WITH HIND III 
  
Figure 17 - Analysis of quality of pTRKH3 by 1% agarose gel electrophoresis. Lane M: Molecular weight 
marker (NYZ DNA Ladder III, NYZTech). Lane U: undigested pDNA, it is shown sc pDNA and traces of linear 
and open circular isoforms; Lane D: Digest pDNA with HIND III.  
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